<DOC>
	<DOCNO>NCT00041587</DOCNO>
	<brief_summary>IL13-PE38QQR oncology drug product consist IL13 ( interleukin-13 ) PE38QQR ( bacteria toxin ) . IL13-PE38QQR protein exhibit cell kill activity variety IL13 receptor-positive tumor cell line indicate may show therapeutic benefit . In reciprocal competition experiment , interaction IL13-PE38QQR IL13 receptor show highly specific human glioma cell . Prior treatment , patient physical neurologic exam , MRI measure extent tumor , tumor biopsy , screen laboratory test . On Day 1 , one two catheter insert directly tumor , CT scan use confirm placement . Each patient receive one IL13-PE38QQR infusion , tumor surgically remove approximately Day 15 . In first group patient , IL13-PE38QQR infuse directly tumor 4 day . Depending effectiveness side effect study drug , duration increase stepwise maximum 7 day subsequent group patient . Once duration infusion determine , dose IL13-PE38QQR increase stepwise ( separate group patient ) , depend effectiveness side effect study drug . The activity drug tumor cell judge examine remove tumor tissue . Patients neurologic exam MRI scan immediately resection every eight week disease progression observe .</brief_summary>
	<brief_title>Pre-operative IL13-PE38QQR Patients With Recurrent Progressive Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : I . To determine maximum-tolerated dose ( MTD ) IL13-PE38QQR deliver continuous infusion via 1 2 intratumoral catheter recurrent progressive malignant glioma . II . To determine : pathologic effect intratumoral IL13-PE38QQR infusion determine Day 15 resection ; neuroradiographic characteristic convection-enhanced drug delivery ; serum level study drug detect appearance antibody study drug . III . To determine proportion patient survive 6 month continuous intratumoral IL13-PE38QQR infusion MTD , follow Day 15 resection , recurrent progressive malignant glioma . IV . To determine : proportion patient remain disease free 6 month ; time progression overall survival patient recurrent progressive malignant glioma infusion IL13-PE38QQR select dose follow resection ; pathologic response rate recurrent progressive malignant glioma IL13-PE38QQR deliver continuous intratumoral infusion MTD ; additional toxicity IL13-PE38QQR administer stereotaxic catheter recurrent progressive malignant glioma MTD ; neuroradiographic characteristic convection-enhanced drug delivery ; serum level study drug detect appearance antibody study drug . PROTOCOL OUTLINE : Patients recurrent progressive supratentorial malignant glioma consider appropriate re-operation eligible either phase study . Each patient tumor biopsy study entry , follow continuous intratumoral infusion IL13-PE38QQR via 1 2 intratumoral catheter , place within enhance portion tumor . Infusion rate hold constant 540 mL/hr ( total ) . Toxicity assess clinical neurologic examination laboratory value . Resection perform Day 15 ( 6-13 day end infusion ) . Pathologic evidence tumor necrosis assess . Follow-up assessment include neurologic examination MRI scan . No anti-tumor treatment administer least 60 day resection ( except progressive disease ) . Patients observe death . Phase I : The infusion duration escalate first cohort 3-6 patient 51.8 mL ( 4 day ) maximum 90.7 mL ( 7 day ) , identify MTD base infusion duration . Once duration determine , IL13-PE38QQR concentration escalate cohort 3-6 patient 90.7 mg maximum 362.8 mg ( assume 7-day infusion ) identify MTD base concentration . Phase II : Patients treat select dose higher MTD estimate proportion patient survive 6 month , time progression survival , pathologic response rate . PROJECTED ACCRUAL : In Phase I , 12-48 patient , 6 center Europe , Israel North America . In Phase II , 35 efficacy evaluable patient , 6 center .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<criteria>Disease Characteristics Must prior histologic diagnosis supratentorial malignant glioma ( Grade 3 4 ) , include glioblastoma multiforme , anaplastic astrocytoma , malignant mixed oligoastrocytoma ( excludes glioma unknown grade pure oligodendroglioma ) . Patients clinical/radiographic diagnosis malignant glioma may register pending histologic confirmation . Must undergone prior surgical resection receive external beam radiotherapy least 48 Gy tumor dose , complete least 8 week prior study . Must recurrent progressive supratentorial tumor compare previous study . Baseline tumor measurement must determine within 2 week prior study . Stereotaxic biopsy study entry must confirm presence glioma ( malignant , unless previously know ) . Recurrent progressive tumor must solid enhance region least 1.0 cm 6.0 cm maximum diameter . ( One satellite lesion permit , separate 3 cm less primary mass . ) Patient Characteristics Age 18 great . Karnofsky Performance Score must least 70 . Hematologic status : Absolute neutrophils least 1,500/mm^3 ; Hemoglobin least 9 gm/dL ; Platelets least 75,000/mm^3 ; PT &amp; PTT within institutional limit normal . Must candidate reoperation . Must recover toxicity prior therapy : least 6 month approve intratumoral chemotherapy ( e.g . carmustine wafer ) ; least 6 week nitrosoureacontaining chemotherapy ; least 4 week investigational agent cytotoxic chemotherapy ; least 2 week vincristine noncytotoxic chemotherapy . Must practice effective method birth control study . Must understand investigational nature study potential risk benefit , sign approve write informed consent prior treatment . No patient tumor cross midline ( tumor involve corpus callosum permit cross midline ) , two foci tumor , nonparenchymal tumor dissemination ( e.g . subependymal leptomeningeal ) . No patient impend herniation ( e.g . midline shift &gt; 1 cm ) , spinal cord compression , uncontrolled seizure requirement immediate palliative treatment . No patient receive localized therapy glioma , e.g . focal singlefraction radiotherapy , brachytherapy , intracerebral infusional chemotherapy . No patient receive concurrent chemotherapy investigational agent ( corticiosteroids permit ) . Female patient must pregnant breastfeeding . No patient unwilling unable follow protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Recurrent resectable supratentorial malignant glioma</keyword>
</DOC>